Search Results 341-350 of 16970 for what is vedolizumab

  1. Discovery's Edge: Hope For Healing With Regenerative Medicine - Mayo Clinic News Network

    Crohn's-related wounds may have met their match in a pioneering regenerative therapy thanks to truly collaborative team science.

  2. Natalizumab (intravenous route) - Side effects & uses - Mayo Clinic

    Vedolizumab. Other Interactions. Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions ...

  3. Jana G. Al Hashash, M.D., M.S. - Doctors and Medical Staff - Mayo Clinic

    ... Crohn's disease and ulcerative colitis. Prior to joining the Inflammatory Bowel Disease Center at Mayo Clinic, she was an Assistant Professor of Medicine at ...

  4. A Study to Evaluate the Safety and Effectiveness of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease - Mayo Clinic

    Clinical Trials · A Study to Evaluate the Safety and Effectiveness of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease · More about ...

  5. A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis - Mayo Clinic

    ... Ulcerative Colitis. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information. Overview.

  6. Hyperbaric Oxygen for Ulcerative Colitis - Mayo Clinic

    ... ulcerative colitis flares as an adjunct to standard medical treatment. Specifically, we will investigate the impact of hyperbaric oxygen therapy on clinical ...

  7. A Study to Evaluate the Safety and Effectiveness of Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease - Mayo Clinic

    For induction: vedolizumab 300 mg. For maintenance: vedolizumab 300 mg every 4 to 8 weeks. Anti-IL-12/23: at least 16 weeks treatment of the approved dose ...

  8. A Study to Assess the Effectiveness and Safety of Risankizumab in Subjects with Ulcerative Colitis - Mayo Clinic

    The purpose of this study is to evaluate safety and efficacy of risankizumab in subjects with ulcerative colitis (UC) in subjects who responded to induction ...

  9. Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease - Mayo Clinic

    The purpose of this study is to determine the effectiveness of RPC1063 in the initial treatment of moderate to severely active Crohn's disease. Participation ...

  10. Irritable bowel syndrome - Diagnosis and treatment - Mayo Clinic

    Lifestyle changes can make a big difference when it comes to managing this common GI disorder. Learn more about symptoms, diagnosis and how to handle ...